A detailed history of Colonial Trust Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Colonial Trust Advisors holds 18 shares of GILD stock, worth $1,623. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18
Previous 18 -0.0%
Holding current value
$1,623
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$63.15 - $72.88 $1,326 - $1,530
-21 Reduced 53.85%
18 $1,000
Q1 2024

May 13, 2024

SELL
$71.58 - $87.29 $2,720 - $3,317
-38 Reduced 49.35%
39 $2,000
Q4 2023

Feb 14, 2024

BUY
$73.27 - $83.09 $366 - $415
5 Added 6.94%
77 $6,000
Q1 2023

May 11, 2023

SELL
$77.31 - $88.08 $541 - $616
-7 Reduced 8.86%
72 $5,000
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $4,923 - $7,068
79 New
79 $6,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Colonial Trust Advisors Portfolio

Follow Colonial Trust Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Colonial Trust Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Colonial Trust Advisors with notifications on news.